Evotec SE
NASDAQ:EVO · NASDAQ Global Select
-$0.02 today
Vol 0.04M · Avg 0.08M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:EVO · Revenue to Net Income
Key Ratios
Analysis
$745.2M of revenue converted into -$196.0M of net income for the selected period. Gross margin is 8.7% and net margin is -30.9%, showing how much revenue survives after costs and taxes. EPS is $-0.55, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $757.3M -5.0% | $797.0M +2.0% | $781.4M +4.0% | $751.4M +21.6% | $618.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $694.6M +1.8% | $682.1M +12.5% | $606.4M +5.0% | $577.4M +23.8% | $466.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $62.7M -45.5% | $114.9M -34.4% | $175.1M +0.6% | $174.1M +14.9% | $151.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 8.3% -6.1pp | 14.4% -8.0pp | 22.4% -0.8pp | 23.2% -1.4pp | 24.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $74.3M +46.2% | $50.9M -25.8% | $68.5M -10.6% | $76.6M +16.7% | $65.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $123.6M -34.3% | $188.2M +11.0% | $169.6M +8.6% | $156.2M +48.1% | $105.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $198.0M -23.1% | $257.4M +15.7% | $222.6M +45.3% | $153.2M +38.6% | $110.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $95.5M -6.0% | $101.6M +9.3% | $93.0M +11.8% | $83.2M +18.2% | $70.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$13.9M +82.8% | -$80.7M -434.3% | $24.1M +141.9% | -$57.6M -118.2% | $316.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -1.8% +8.3pp | -10.1% -13.2pp | 3.1% +10.8pp | -7.7% -58.9pp | 51.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$135.3M +5.1% | -$142.5M -200.0% | -$47.5M -327.9% | $20.9M -49.1% | $41.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -17.9% +0.0pp | -17.9% -11.8pp | -6.1% -8.9pp | 2.8% -3.9pp | 6.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $4.2M +74.5% | $2.4M -73.7% | $9.3M +11.1% | $8.3M +266.9% | $2.3M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $13.9M +18.6% | $11.7M -0.3% | $11.7M -10.7% | $13.2M +42.1% | $9.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $12.0M +123.3% | -$51.5M -55.5% | -$33.1M +81.1% | -$174.8M -189.2% | $196.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$123.3M +36.4% | -$194.0M -140.7% | -$80.6M +47.7% | -$154.0M -165.0% | $237.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -16.3% +8.1pp | -24.3% -14.0pp | -10.3% +10.2pp | -20.5% -58.8pp | 38.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$23.9M -1236.1% | $2.1M -36.7% | $3.3M -84.7% | $21.7M +1.1% | $21.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$99.4M +49.3% | -$196.1M -133.7% | -$83.9M +52.2% | -$175.7M -181.5% | $215.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | -13.1% +11.5pp | -24.6% -13.9pp | -10.7% +12.6pp | -23.4% -58.2pp | 34.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +50.0% | -$1 -143.5% | -$0 +53.1% | -$0 -175.4% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +50.0% | -$1 -143.5% | -$0 +53.1% | -$0 -175.4% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $355.2M +0.5% | $353.3M -0.2% | $353.9M +0.1% | $353.3M +6.2% | $332.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $355.2M +0.2% | $354.6M +0.2% | $353.9M +0.1% | $353.4M +6.2% | $332.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.31B
Pharvaris N.V.
NASDAQ:PHVS
$2.28B
NovoCure Limited
NASDAQ:NVCR
$1.72B
Harrow Health, Inc.
NASDAQ:HROW
$1.57B
Teladoc Health, Inc.
NYSE:TDOC
$1.40B
Alvotech
NASDAQ:ALVO
$1.21B
Schrödinger, Inc.
NASDAQ:SDGR
$1.16B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Pacira BioSciences, Inc.
NASDAQ:PCRX
$883.07M
Tilray Brands, Inc.
NASDAQ:TLRY
$562.74M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does EVO generate?
Evotec SE (EVO) reported $757.26M of revenue in fiscal 2025.
Is EVO profitable?
Evotec SE (EVO) reported -$99,431,462.00 of net income, with a net margin of -13.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.